利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.067 秒)

    PDGFRBETA-FC FUSION PROTEINS AND USES THEREOF
    3.
    发明申请
    PDGFRBETA-FC FUSION PROTEINS AND USES THEREOF 审中-公开
    PDGFRBETA-FC融合蛋白及其用途

    公开(公告)号：US20160009776A1

    公开(公告)日：2016-01-14

    申请号：US14328487

    申请日：2014-07-10

    申请人： Bayer Pharma Aktiengesellschaft

    发明人： Lars Linden ,  Thomas Schlange ,  Andreas Wilmen ,  Mark Trautwein ,  Tibor Schomber ,  Michael Bottger ,  Jürgen Klar ,  Simone Greven

    IPC分类号： C07K14/49

    CPC分类号： C07K14/49 ,  C07K2319/30

    摘要： The present disclosure provides PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of PDGFRbeta, or a biologically active fragment thereof, a linker and a Fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g. cancer, ocular neovascular disorders or nephropathies. The disclosure also provides methods for treating ocular neovascular disorders with these fusion proteins without increasing vascular leakage. Such PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, exhibit increased terminal half time in the eye. Also provided are nucleic acid sequences encoding the foregoing PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

    摘要翻译： 本公开提供了包含PDGFRβ或其生物活性片段，连接体和Fc结构域的细胞外结构域的PDGFRβ-Fc融合蛋白或其生物活性片段，其中所述融合蛋白结合一种或多种血小板衍生生长 因子配体具有高亲和力。 因此，PDGFRβ-Fc融合蛋白或其生物活性片段可用于治疗病理性新血管形成和纤维化，例如， 癌症，眼新生血管性疾病或肾病。 本公开还提供了用这些融合蛋白治疗眼新生血管障碍而不增加血管渗漏的方法。 这种PDGFRβ-Fc融合蛋白或其生物活性片段在眼中表现出增加的终末半衰期。 还提供了编码前述PDGFRβ-Fc融合蛋白或其生物活性片段的核酸序列，含有其的载体，药物组合物和具有使用说明书的试剂盒。